On April 22, 2026, Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced that it had entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The deal structure included $100 million in cash at closing, subject to customary working capital and other adjustments, plus up to $35 million of contingent earn-out based on future performance, with up to $15 million of the closing payment potentially placed in escrow until certain items were satisfied. The business generated $50 million of revenue and $17 million of adjusted EBITDA in 2025 and includes approximately 220 employees. The transaction closed on May 8, 2026, pursuant to the terms of the Purchase Agreement, with cash consideration of $85.0 million at closing and an additional $15 million placed in escrow. For Certara, the divestiture sharpens its strategic focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence and frees capital to accelerate AI-integrated modeling and simulation across the drug development lifecycle. For Veristat, a science-first full-service CRO and consultancy advancing complex therapies through the drug development lifecycle to regulatory submission, the acquisition is supported by WindRose Health Investors, LLC, a New York-based healthcare private equity firm, and adds 200+ regulatory and medical writing experts to its platform.